Linzagolix
| Clinical data | |
|---|---|
| Pronunciation | /ˌlɪnzəˈɡoʊlɪks/ LINZ-ə-GOH-liks  | 
| Trade names | Yselty | 
| Other names | KLH-2109; OBE-2109 | 
| Routes of administration  | By mouth | 
| Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin | 
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
  | |
| CAS Number | 
  | 
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | 
  | 
| Chemical and physical data | |
| Formula | C22H15F3N2O7S | 
| Molar mass | 508.42 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
Linzagolix, sold under the brand name Yselty, is a medication used in the treatment of uterine fibroids and endometriosis. Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) developed by Kissei Pharmaceutical and ObsEva.
In June 2022, it was approved for medical use in the European Union and in the United Kingdom.